ADMA Stock Rises 9% Pre-Market: Biologics Firm Rebuts Culper Short Report, Says Asceniv Growth ‘Steady’

Adma Biologics (ADMA) remained in the spotlight as it pushed back against a short report from Culper Research, calling the claims “unsubstantiated” and “misleading” as it sought to reassure investors about demand trends for its flagship therapy, Asceniv.

ADMA stock jumped 9% in pre-market trading on Friday.

The company said demand for its immune globulin therapy, Asceniv, has been steadily growing over the past two years, supported by data from distributors and end users. Culper had stated that Adma inflated Asceniv’s sales by 40% to 76%. 

Addressing channel stuffing concerns, Adma said distributor inventory levels are consistent with industry norms, and maintaining a safety stock reflects normal supply dynamics rather than excess buildup. Culper had alleged that Adma’s revenue declined 3% in 2025, while the company reported a 20% growth.

Get updates to this developing story on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.